Search

Your search keyword '"Allais, G."' showing total 416 results
Start Over Author "Allais, G."
416 results on '"Allais, G."'

1. Improvement in Diagnostic-Therapeutic Care Pathways for Women with Migraine: An Italian Delphi Panel

Author

Cevoli, S, Barbanti, P, Finocchi, C, Benedan, L, Mariani, P, Orthmann, N, Bauleo, S, Brusa, P, Cianci, D, Marozio, L, Masseroni, S, Sangermani, R, Frediani, F, Allais, G, Barbanti,P, Finocchi,C, Benedan,L, Mariani,P, Frediani , F, Allais,G, Cevoli, S, Barbanti, P, Finocchi, C, Benedan, L, Mariani, P, Orthmann, N, Bauleo, S, Brusa, P, Cianci, D, Marozio, L, Masseroni, S, Sangermani, R, Frediani, F, Allais, G, Barbanti,P, Finocchi,C, Benedan,L, Mariani,P, Frediani , F, and Allais,G

Abstract

Background: Migraine is a highly underestimated and burdensome disease. Real-world studies evidence that migraine is more frequent and severe in women than men. However, to this day, no diagnostic-therapeutic pathways exist to satisfy the specific needs of female patients. Methods: In this study, migraine experts, specialists in women’s health, patient, and decision makers, analyzed the diagnostic and therapeutic options for women with migraine across various ages and health conditions within the Italian healthcare system. A Delphi approach was used to formulate statements and achieve a consensus. Results: Gaps in clinical practice were identified, and strategies to accommodate women’s needs were proposed. The experts agreed that a socio-behavioral intervention should be planned before any pharmacological treatment in pediatric/adolescent female patients and that the assessment of migraine with aura is considered crucial for adult women requiring contraceptive therapy. Acupuncture emerged as an effective treatment for pregnant and breastfeeding women, and hormone-replacement therapy selection in menopausal patients requires careful consideration to mitigate safety risks. The experts highlighted the absence of literature and guidelines for the management of migraine in women undergoing assisted reproductive procedures or oncological treatment. In light of these observations, the experts advocated the establishment of multidisciplinary collaborations between neurologists/headache specialists and other healthcare professionals, including general practitioners, pediatricians, gynecologists, and oncologists. Comprehensive migraine education for all healthcare professionals potentially involved in managing the disease, including pharmacists, was emphasized. Efforts to increase migraine awareness among women should be prioritized. Conclusion: The insights gained from this Italian consensus study should serve to develop an improved, female-specific pathway to diagnose and t

Published
2024

2. Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine

Author

Allais G and Benedetto C

Subjects
Migraine, frovatriptan, menstrual, dexketoprofen, triptans, migraine with aura, Therapeutics. Pharmacology, RM1-950
Abstract

Gianni Allais, Chiara Benedetto Department of Surgical Sciences, Women’s Headache Center, University of Turin, Turin, Italy Abstract: Migraine is a common neurovascular disorder, affecting millions of people worldwide. Current guidelines recommend triptans as first-line treatment for moderate-to-severe migraine attacks. Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours). Three double-blind, randomized crossover preference studies have been recently conducted, assessing efficacy and safety of frovatriptan versus rizatriptan, zolmitriptan, and almotriptan, respectively. Frovatriptan showed favorable tolerability and sustained effect, with a significantly lower rate of relapse over 48 hours versus the other triptans. These findings were confirmed in a series of analyses of patient subsets from the three studies, including patients with menstrually related and oral contraceptive-induced migraine, hypertension, obesity, weekend migraine, as well as patients with migraine with aura. In all patient subsets analyzed, lower headache recurrence rates were observed versus the comparator triptans, indicating a more sustained pain-relieving effect on migraine symptoms. A further randomized, double-blind study demonstrated that frovatriptan given in combination with the fast-acting cyclooxygenase inhibitor dexketoprofen provided improved migraine pain-free activity at 2 hours, and gave more sustained pain-free activity at 24 hours, versus frovatriptan alone. These benefits were observed both when the combination was administered early (1 hour after onset). Different pharmacokinetic, but synergistic, properties between frovatriptan and dexketoprofen may make the combination of these agents particularly effective in migraine treatment, with rapid onset of action and sustained effect over 48 hours. These benefits, together with potential cost-effectiveness advantages versus other triptans could drive selection of the most appropriate treatment for acute migraine attacks. Keywords: migraine, frovatriptan, menstrual, dexketoprofen, triptans, migraine with aura

Published
2016

3. Emicrania: la donna

Author

Allais, G. B., Benedetto, C., Bussone, Gennaro, Casucci, Gerardo, Frediani, Fabio, Manzoni, Gian Camillo, and Bonavita, Vincenzo

Published
2008
Full Text
View/download PDF

39. Electrical and structural studies of copper and nickel precipitates in a Sigma = 25 silicon bicrystal

Author

Rizk, R., Portier, X., Allais, G., and Nouet, G.

Subjects
Copper -- Analysis, Nickel -- Analysis, Silicon crystals -- Research, Physics
Abstract

Deep-level transient spectroscopic analysis of silicon bicrystal reveals continuous energy level distributions between minus 0.20 and minus 0.38 eV. The bicrystals contaminated with Cu or Ni reveal interface trap characteristics of quenched Cu precipitates at minus 0.54 eV. Introduction of Ni in 'copper-free' bicrystals causes a discrete energy level at minus 0.50 eV.

Published
1994

42. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial

Author

Diener, H, Agosti, R, Allais, G, Bergmans, P, Bussone, G, Davies, B, Ertas, M, Lanteri Minet, M, Reuter, U, Del Río, MS, Schoenen, J, Schwalen, S, van Oene, J, TOPMAT MIG 303 Investigators Group, C. Lampl, T. Berger, J. Jacquy, L. Herroelen, P. Louis, J. Schoenen, I. Milanov, Z. Zahariev, S. Bozhinov, P. Dočekal, M. Grünermelová, G. Waberžinek, P. Tfelt Hansen, M. Groenbech Jensen, I. Tsiropoulos, R. Kirkeby, M. J. Rasmussen, D. Valade, H. Massiou, C. Sereni, A. Donnet, M. Lanteri Minet, C. Lucas, G. Mick, A. Pradalier, E. Guegan Massardier, H. C. Diener, S. Evers, U. Reuter, A. Straube, D. Mitsikostas, K. Karageorgiou, I. Milonas, G. Georgiadis, G. Gyula, Á. Judit, H. Péter, V. László, O. Hardiman, B. Sweeny, L. Grazzi, B. Colombo, G. Bruzzone, A. Quattrone, C. Benedetto, G. D'Andrea, P. Barbanti, R. De Simone, F. Valguarnera, M. A. Al Jumah, A. Al Tahan, I. Monstad, R. sj, R. Salvesen, LJ Stovner, H. Kwiecinski, W. Fryze, D. Pruchnik Wolinska, R. Motyl, W. Kozubsk, K. Ulatowska Blaszyk, A. Prusinski, L. Cunha, J. Pereira Monteiro, P. Esperança, A. Boyko, A. Skoromets, T. Pogačnik, T. Hojs Fabjan, M. Sánchez Del Río, R. Agosti, F. Donati, B. Tettenborn, M. Siccoli, A. Siva, M. Ertaş, M. Zarifoğlu, B. Davies, P. Davies, D. Bates, M. Fontebasso, P. Cleland, S. Lipscombe, A. Dowson, M. Lawden, S. McPhee, B. Calder, FERRARESE, CARLO, Diener, H, Agosti, R, Allais, G, Bergmans, P, Bussone, G, Davies, B, Ertas, M, Lanteri Minet, M, Reuter, U, Del Río, M, Schoenen, J, Schwalen, S, van Oene, J, TOPMAT MIG 303 Investigators, G, C., L, T., B, J., J, L., H, P., L, J., S, I., M, Z., Z, S., B, P., D, M., G, G., W, P., T, I., T, R., K, M. J., R, D., V, H., M, C., S, A., D, M., L, G., M, A., P, E., G, H. C., D, S., E, U., R, A., S, D., M, K., K, G., G, Á., J, H., P, V., L, O., H, B., S, L., G, B., C, Ferrarese, C, G., B, A., Q, C., B, G., D, P., B, R., D, F., V, M. A., A, A., A, I. Monstad, R, R., S, Lj, S, H., K, W., F, D., P, R., M, W., K, K., U, L., C, J., P, P., E, A., B, T., P, T., H, M., S, R., A, F., D, B., T, M., E, M., Z, B., D, D., B, M., F, P., C, S., L, and S., M

Subjects
Adult, Male, Topiramate, medicine.medical_specialty, Time Factors, Time Factor, Adolescent, Migraine Disorders, Neuroprotective Agent, Placebo-controlled study, Fructose, Placebo, Severity of Illness Index, Drug Administration Schedule, Migraine Disorder, Double-Blind Method, Internal medicine, Clinical endpoint, medicine, Humans, Aged, Cross-Over Studies, Intention-to-treat analysis, Dose-Response Relationship, Drug, business.industry, Middle Aged, medicine.disease, Crossover study, Surgery, Discontinuation, Neuroprotective Agents, Treatment Outcome, Migraine, Quality of Life, Female, Neurology (clinical), business, Human, medicine.drug
Abstract

BACKGROUND: Use of preventive therapy for migraine is often recommended for only 6-9 months, but no randomised, placebo-controlled trials have investigated migraine frequency after the end of prophylaxis. We assessed the effects of discontinuation of topiramate after a treatment period of 6 months. METHODS: 818 patients who have migraines were enrolled from 88 clinics in 21 countries. After a 4-8-week lead-in period, patients received topiramate in a 26-week open-label phase. Daily dose was increased from 25 mg to 100 mg in steps of 25 mg every week; the dose could be adjusted further in the range 50-200 mg/day, but was stable for the final 4 weeks. Patients were randomly assigned to continue this dose or switch to placebo for a 26-week double-blind phase. The primary endpoint was the difference in number of days with migraine during the last 4 weeks of the double-blind phase compared with the last 4 weeks of the open-label phase. Analysis was by intention to treat. This trial is registered with EudraCT, number 2005-000321-29. FINDINGS: 559 patients (68.3%) completed the open-label phase; 514 entered the double-blind phase and were assigned to topiramate (n=255) or placebo (n=259). The mean increase in number of migraine days was greater in the placebo group (1.19 days in 4 weeks, 95% CI 0.71 to 1.66; p

Published
2007
Full Text
View/download PDF

43. Erratum to: Early (≤1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group study

Author

Allais G, Bussone G, Tullo V, Cortelli P, Valguarnera F, Barbanti P, Sette G, Frediani F, D'Arrigo G, d'Onofrio F, Curone M, Colombo B, Omboni S, Benedetto C., COMI , GIANCARLO, Allais, G, Bussone, G, Tullo, V, Cortelli, P, Valguarnera, F, Barbanti, P, Sette, G, Frediani, F, D'Arrigo, G, D'Onofrio, F, Comi, Giancarlo, Curone, M, Colombo, B, Omboni, S, and Benedetto, C.

Published
2015

46. Electrical and structural studies of copper and nickel precipitates in a Σ=25 silicon bicrystal.

Author

Rizk, R., Portier, X., Allais, G., and Nouet, G.

Subjects
DEEP level transient spectroscopy, SILICON, COPPER, NICKEL
Abstract

Presents a study which performed deep-level transient spectroscopy (DLTS) measurements of electronic defect states in a coincidence grain boundary (GB) in silicon after quenching of heat-treated samples containing copper and/or nickel. Preparation of the samples; Application of the DLTS to GB studies; Result of the DLTS spectra and transmission electron microscopy micrographs of a sample heavily contaminated with copper.

Published
1994
Full Text
View/download PDF

48. Headache, anxiety and depressive disorders: the HADAS study. J Headache Pain

Author

Beghi E, Bussone G, D'Amico D, Cortelli P, Cevoli S, Manzoni GC, Torelli P, Tonini MC, Allais G, D'Onofrio F, Genco S, Moschiano F, Beghi M, Salvi S., DE SIMONE, ROBERTO, Beghi, E, Bussone, G, D'Amico, D, Cortelli, P, Cevoli, S, Manzoni, Gc, Torelli, P, Tonini, Mc, Allais, G, DE SIMONE, Roberto, D'Onofrio, F, Genco, S, Moschiano, F, Beghi, M, and Salvi, S.

Abstract

Headache, anxiety and depressive disorders: the HADAS study J Headache Pain (2010) 11:141–150 Ettore Beghi • Gennaro Bussone • Domenico D’Amico • Pietro Cortelli • Sabina Cevoli • Gian Camillo Manzoni • Paola Torelli • Maria Clara Tonini • Giovanni Allais • Roberto De Simone • Florindo D’Onofrio • Sergio Genco • Franca Moschiano • Massimiliano Beghi • Sara Salvi Abstract The objective of this paper was to assess prevalence and characteristics of anxiety and depression in migraine without aura and tension-type headache, either isolated or in combination. Although the association between headache and psychiatric disorders is undisputed, patients with migraine and/or tension-type headache have been frequently investigated in different settings and using different tests, which prevents meaningful comparisons. Psychiatric comorbidity was tested through structured interview and the MINI inventory in 158 adults with migraine without aura and in 216 persons with tension-type headache or migraine plus tension-type headache. 49 patients reported psychiatric disorders: migraine 10.9%, tension-type headache 12.8%, and migraine plus tensiontype headache 21.4%. The MINI detected a depressive episode in 59.9, 67.0, and 69.6% of cases. Values were 18.4, 19.3, and 18.4% for anxiety, 12.7, 5.5, and 14.2%, for panic disorder and 2.3, 1.1 and 9.4% (p = 0.009) for obsessive–compulsive disorder. Multivariate analysis showed panic disorder prevailing in migraine compared with the other groups (OR 2.9; 95% CI 1.2–7.0). The association was higher (OR 6.3; 95% CI 1.4–28.5) when migraine (with or without tension-type headache) was compared to pure tension-type headache. This also applied to obsessive–compulsive disorder (OR 4.8; 95% CI 1.1– 20.9) in migraine plus tension-type headache. Psychopathology of primary headache can reflect shared risk factors, pathophysiologic mechanisms, and disease burden.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results